Skip to main content

Advancell participates in European project Carcinogenomics

By 11 de November de 2009November 18th, 2020No Comments
< Back to news

Advancell participates in European project Carcinogenomics

Bio-tech firm Advancell –located at Barcelona Science Park– leader in nano-medicine research and cellular methods for in-vitro research that deals with unresolved needs in health and wellbeing through its products and services, is the only Spanish company that will participate in the meeting, starting today until 13th November, that brings together 18 research groups from 11 European countries who form part of the Carcinogenomics project. The project is directed and financed by the EU and its main objective is the development of in-vitro methods to guarantee the evaluation of carcinogenic potential (that is the capacity to cause cancer) in chemical compounds whilst avoiding animal experiments.

Advancell has a key role in the five year project which concludes in 2011 and is responsible for the analysis of metabolic capacity of various cellular models used in the project. As such, the company is developing new in-vitro models and determining the toxicity of carcinogenic compounds via the use of cellular models where metabolic activity is present and which mimic the function of the principal affected organs such as liver, lung and kidney. The results of the Project will be used as a base for an in-vitro strategy to determine the carcinogenic potential of chemical products, such as those used in cleaning and personal hygiene products, paints etc., in addition to guaranteeing improved safety in both existing and new products.

Advancell, via its business unit, Advancell Alternative Testing, is a specialist in the development and application of tests based on in-vitro cellular models for the use of evaluating the safety and efficiency of chemical compounds. In-vitro models are characterised by their use of human cells to predict pharmaceutical and toxicological effects of a new medicine on a human being, thereby reducing animal experimentation.